Lupin's shares surged by 2.2% following tentative U.S. FDA approval for its generic HIV treatment, Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets. This positions Lupin to enter a significant U.S. market segment with estimated annual sales of $16.237 billion. The drug, a generic version of Gilead Sciences’ Biktarvy, will be manufactured at Lupin’s Nagpur facility.
Finance
September 25, 2025
Lupin shares gain 2% after USFDA approval for HIV drug
Unknown Author
Advertisement
Related Articles
If Notre Dame Wants Another College Football Playoff …
Notre Dame's mission? The Fighting Irish must do more than just win these final seven …
3 hours, 17 minutes ago
229% inflation: How ‘Binance dollars’ became Venezuela’s real …
Venezuela turns to USDT as hyperinflation bites, with merchants pegging prices to Binance P2P dollar …
3 hours, 18 minutes ago
Prediction: Tesla Stock May Be "Dreadful" in 2026
Tesla (NASDAQ: TSLA) investors should prepare for a rocky 2026. At least that's what certain …
3 hours, 28 minutes ago
1 Warren Buffett Stock That Could Go Parabolic …
You may be surprised to learn that the largest investor in Sirius XM Holdings (NASDAQ: …
3 hours, 31 minutes ago